INOZYME PHARMA, INC. Accumulated Other Comprehensive Income
INOZYME PHARMA, INC. had Accumulated Other Comprehensive Income of -$5.00 thousand as of 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2025-05-14
- 2025-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$5.00K.
- 2024-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $69.00K.
- 2024-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $186.00K.
- 2024-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$103.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2025-03-31 | -$5.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $69.00K 10-Q · filed 2025-05-14 |
| 2024-09-30 | $186.00K 10-Q · filed 2024-11-05 |
| 2024-06-30 | -$103.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$105.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $41.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | -$78.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $51.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$36.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$205.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | -$477.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$397.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$129.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $18.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $3.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $18.00K 10-Q · filed 2021-08-11 |
| 2021-03-31 | $12.00K 10-Q · filed 2021-05-12 |
| 2020-12-31 | $2.00K 10-K · filed 2022-03-15 |
| 2020-06-30 | $13.00K 10-Q · filed 2020-09-03 |
| 2019-12-31 | $5.00K 10-K · filed 2021-03-25 |